SCH66336

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center

Conditions

Cancer of Head and NeckCarcinoma, Squamous CellHead and Neck CancerMyelogenous Leukemia, Chronic

Phase 1

A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell Cancer

CompletedNCT00038584

M.D. Anderson Cancer CenterCancer of Head and Neck, Carcinoma, Squamous Cell

Start: 1999-06-30End: 2004-11-30Updated: 2018-10-30

4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)

TerminatedNCT00102635

M.D. Anderson Cancer CenterHead and Neck Cancer

Start: 2005-01-20End: 2006-11-30Updated: 2018-11-15

Phase 2

Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

CompletedNCT00038597

M.D. Anderson Cancer CenterMyelogenous Leukemia, Chronic

Start: 2001-04-30End: 2004-05-07Updated: 2018-10-30